

Gwo-Tzer Ho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5274167/publications.pdf>

Version: 2024-02-01

27
papers

3,075
citations

377584

21
h-index

620720

26
g-index

127
all docs

127
docs citations

127
times ranked

4989
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitochondria and Inflammatory Bowel Diseases: Toward a Stratified Therapeutic Intervention. Annual Review of Physiology, 2022, 84, 435-459.	5.6	40
2	Intestinal Protein Characterisation of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in Inflammatory Bowel Disease (IBD) and Fatal COVID-19 Infection. Inflammation, 2022, 45, 567-572.	1.7	10
3	Neutrophil Extracellular Traps in Inflammatory Bowel Disease: Pathogenic Mechanisms and Clinical Translation. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 321-333.	2.3	73
4	The MARVEL trial: a phase 2b randomised placebo-controlled trial of oral MitoQ in moderate ulcerative colitis. Immunotherapy Advances, 2021, 1, .	1.2	6
5	Resolution of Inflammation and Gut Repair in IBD: Translational Steps Towards Complete Mucosal Healing. Inflammatory Bowel Diseases, 2020, 26, 1131-1143.	0.9	47
6	Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Research, 2020, 9, 294.	0.8	111
7	IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut, 2019, 68, 1953-1960.	6.1	134
8	Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes. Digestive Diseases and Sciences, 2019, 64, 1660-1667.	1.1	25
9	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology, 2018, 154, 1320-1333.e10.	0.6	116
10	Mitochondrial DNA Is a Pro-Inflammatory Damage-Associated Molecular Pattern Released During Active IBD. Inflammatory Bowel Diseases, 2018, 24, 2113-2122.	0.9	87
11	PWE-019...Day of admission results predict outcome in acute ulcerative colitis. , 2018, , .		0
12	Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies?. Clinical Gastroenterology and Hepatology, 2017, 15, 76-78.	2.4	0
13	Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases. F1000Research, 2017, 6, 169.	0.8	127
14	Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2016, 111, 1796-1805.	0.2	88
15	Biomarkers in Search of Precision Medicine in IBD. American Journal of Gastroenterology, 2016, 111, 1682-1690.	0.2	45
16	Pathogenesis of Crohn's disease. F1000prime Reports, 2015, 7, 44.	5.9	73
17	Guidelines for the management of inflammatory bowel disease in adults. Gut, 2011, 60, 571-607.	6.1	1,127
18	Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study. Inflammatory Bowel Diseases, 2011, 17, 937-946.	0.9	21

#	ARTICLE	IF	CITATIONS
19	Analysis of Germline GLI1 Variation Implicates Hedgehog Signalling in the Regulation of Intestinal Inflammatory Pathways. PLoS Medicine, 2008, 5, e239.	3.9	63
20	Genetics of the innate immune response in inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 338-355.	0.9	71
21	The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. European Journal of Gastroenterology and Hepatology, 2005, 17, 1379-1385.	0.8	51
22	Multidrug Resistance (MDR1) Gene in Inflammatory Bowel Disease: A Key Player?. Inflammatory Bowel Diseases, 2005, 11, 1013-1019.	0.9	16
23	Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology, 2005, 128, 288-296.	0.6	179
24	The Contribution of OCTN1/2 Variants Within the IBD5 Locus to Disease Susceptibility and Severity in Crohn's Disease. Gastroenterology, 2005, 129, 1854-1864.	0.6	125
25	Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Alimentary Pharmacology and Therapeutics, 2004, 19, 1079-1087.	1.9	240
26	Pharmacogenetics and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 148-158.	0.9	14
27	Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?. Gut, 2003, 52, 759-766.	6.1	173